Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Status:
Completed
Trial end date:
2019-06-07
Target enrollment:
Participant gender:
Summary
The purpose of this first in human study is to assess safety, tolerability, PK and
preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as
S64315) as single agent administered intravenously (i.v.) in adult patients with refractory
or relapsed lymphoma or multiple myeloma.